Anixa biosciences initiates dosing in fourth cohort in its ovarian cancer car-t clinical trial

Fourth cohort dose is three million car positive cells; thirty times higher than the first cohort dose san jose, calif. , june 23, 2025 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing phase 1 clinical trial evaluating its novel chimeric antigen receptor-t cell (car-t) therapy for recurrent ovarian cancer.
CAR Ratings Summary
CAR Quant Ranking